Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia

Nephrol Dial Transplant. 2004 Aug;19(8):2137-9. doi: 10.1093/ndt/gfh319.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies / immunology
  • Cyclosporine / therapeutic use
  • Darbepoetin alfa
  • Drug Resistance
  • Epoetin Alfa
  • Erythropoietin / administration & dosage*
  • Erythropoietin / adverse effects*
  • Erythropoietin / analogs & derivatives*
  • Erythropoietin / immunology
  • Erythropoietin / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Recombinant Proteins
  • Red-Cell Aplasia, Pure / chemically induced*
  • Red-Cell Aplasia, Pure / immunology
  • Renal Dialysis*
  • Reticulocyte Count
  • Retreatment

Substances

  • Antibodies
  • Immunosuppressive Agents
  • Recombinant Proteins
  • Erythropoietin
  • Darbepoetin alfa
  • Epoetin Alfa
  • Cyclosporine